Chemotherapy versus best supportive care in stage IV non-small cell lung cancer, non metastatic to the brain.
Open Access
- 1 April 2001
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Revista Do Hospital Das Clinicas
- Vol. 56 (2), 53-58
- https://doi.org/10.1590/s0041-87812001000200004
Abstract
Stage IV non-small cell lung cancer is a fatal disease, with a median survival of 14 months. Systemic chemotherapy is the most common approach. However the impact in overall survival and quality of life still a controversy.Keywords
This publication has 13 references indexed in Scilit:
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- Chemotherapy vs Supportive Care in Advanced Non-Small-Cell Lung CancerChest, 1994
- Cisplatin-Cyclophosphamide-Mitomycin Combination Chemotherapy With Supportive Care Versus Supportive Care Alone for Treatment of Metastatic Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1993
- Combined Chemotherapy and Radiotherapy versus Best Supportive Care in the Treatment of Inoperable Non-Small-Cell Lung CancerOncology, 1992
- Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer.Journal of Clinical Oncology, 1990
- Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?Cancer, 1989
- Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.Journal of Clinical Oncology, 1988
- A New International Staging System for Lung CancerChest, 1986
- Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinomaCancer, 1982
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977